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From a therapeutic viewpoint, there 
is much to be gained from a detailed 
understanding of the biology of effec-
tor molecules such as Fc receptors and 
complement. Indeed, knowledge of the 
interaction of IgG with such molecules 
has been central to the development 
of improved mAbs with altered func-
tions and transformed half-lives, tailored 
for particular therapeutic applications. 
Examples include mAbs designed to 
maximize complement recruitment1 or to 
enhance Fc receptor engagement and trig-
gering of ADCC,2-5 or conversely, variants 
engineered to be unable to engage comple-
ment6 or Fc receptors.7 Glycoengineering 
of IgG Fc offers an alternative means to 
modify effector function capabilities,8 
while development of IgG mutants that 
display extended or altered serum half-
lives has been driven through exhaustive 
analysis of the interaction with FcRn.9,10
Despite the appreciable advances that 
have been made in unravelling the various 
facets of Fc receptor biology, new infor-
mation pertinent to mAb engineering 
continues to emerge. A flavor of some of 
these new advances will be given below. 
They span novel receptors and receptor 
roles, structure-function relationships, 
the molecular architecture of signaling 
complexes, the influence of the membrane 
lipid environment and scaffolding interac-
tions, isotype considerations, through to 
technical innovations likely to inform the 
field.
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Remarkably, new receptors that have 
previously eluded characterization are 
now being described. These include the 
IgM receptor, which evidence indicates 
is a molecule also known as TOPO/Fas 
apoptotic inhibitory molecule 3 whose 
gene lies close to other known immuno-
globulin receptors on chromosome 1,11 
and a receptor for IgD recently docu-
mented on basophils.12 Moreover, we are 
seeing an appreciation of new roles for 
existing Fc receptors. An example is the 
demonstration in a transgenic study that 
human FcγRIIa can trigger active and 
passive anaphylaxis and airway inflam-
mation. Moreover, human mast cells, 
monocytes and neutrophils were shown 
to produce anaphylactogenic mediators 
when FcγRIIA was engaged.13 Hence IgG 
may contribute to allergic and anaphy-
lactic reactions in humans by engaging 
FcγRIIa.
Exciting new structural information 
on Fc receptors and their ligands is emerg-
ing. An important example is the solving 
of the X-ray crystal structure for human 
FcγRI.14 While the structural information 
supports a ligand binding mode similar to 
those of FcγRII or FcγRIII, the FG-loop 
in domain 2 of FcγRI with its conserved 
one-residue deletion appears critical for 
high affinity IgG binding. A second 
example concerns the high responder/
low responder (HR/LR) polymorphisms 
of FcγRIIa, which are linked to sus-
ceptibility to infections, autoimmune 
diseases, and the efficacy of therapeutic 
Abs. New insights into these differences 
have been provided by the recent solving 
of the structure for the complex of the HR 
allele with IgG Fc.15 Third, understand-
ing of the human IgE-FcεRI interaction 
has moved forward significantly through 
the solving of the X-ray crystal structure 
of the complex of FcεRI and the entire Fc 
region of IgE (comprising domains Cε2, 
Cε3 and Cε4).16 In a final example, the 
structural basis for the improved efficacy 
of nonfucosylated mAbs has been investi-
gated.17 The X-ray crystal structure of the 
complex between nonfucosylated IgG Fc 
and a soluble form of FcγRIIIa carrying 
two N-linked glycans showed that one of 
two receptor glycans interacts with non-
fucosylated Fc to stabilize the complex. 
It is proposed that when the Fc glycan is 
fucosylated this interaction is inhibited 
due to steric hindrance and, together with 
the negative effects of Fc fucosylation on 
the dynamics of the receptor binding site, 
this provides a rationale for the improved 
ADCC displayed by nonfucosylated IgG.
A question of interest is precisely how 
Fc receptors bound to antibody ligands 
organize themselves within signaling com-
plexes in the cell membrane. Some intrigu-
ing clues to this conundrum of molecular 
architecture are now surfacing. In mast 
cells, FcεRI molecules loaded with IgE 
form a synapse when presented with anti-
gen that is mobile within a lipid bilayer, 
via coalescence into large cholesterol-rich 
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Interest in Fc receptors continues 
unabated, and the contribution that the 
field can make to mAb development 
and optimisation is unquestionable. The 
FASEB SRC on Immunoreceptors will 
serve as a forum for discourse on the above 
issues and much more, providing invalu-
able information and networking oppor-
tunities for all those interested in ways to 
maximize the efficacy of mAbs and mAb-
based reagents. Registration is open until 
24 June 2012.
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clusters.18 Of particular relevance to the 
therapeutic setting, clustering of receptors 
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mediated by tumor-specific mAb, cluster-
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myeloid cells.
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